Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Minster Pharmaceuticals PLC

Division of Proximagen Ltd.

Latest From Minster Pharmaceuticals PLC

APPOINTMENT ROUND UP: GlaxoSmithKline, Sanofi, Immune Design, Clinigen, Advaxis, Nanobiotix and Kite Pharma

This week's round up includes CEO appointments by GSK, who has appointed Brian McNamara CEO of the company's consumer unit, Clinigen and The Grünenthal Group; and executive appointments by Sanofi, where Alan Main has joined as executive vice president consumer healthcare global business unit, Immune Design, Advaxis, Kite Pharma and Bavarian Nordic.


Upsher-Smith To Buy U.K. Biotech Partner Proximagen For $347 Million

Proposed acquisition mimics other recent M&A deals, like Sanofi/Genzyme, with inclusion of contingent-value rights pegged to success of two clinical candidates.

BioPharmaceutical United States

Pharming nominates CFO

The board of supervisory directors at Pharming (the Netherlands) has nominated Dr Karl Keegan for appointment as chief financial officer and member of the board of management. The company will hold an extraordinary general meeting of shareholders on 1 October to request approval for Dr Keegan's appointment as a board member. Dr Keegan was most recently CFO of Minster Pharmaceuticals, a drug development company which was acquired by Proximagen Neuroscience in February. Before that, he worked at Canaccord Adams as managing director, UK head of equity research and global head of life sciences research and as a biotechnology analyst at several investment banks, including Banc of America, UBS and Dresdner Kleinwort Benson.

Netherlands Companies

Proximagen divests second Minster programme

Proximagen is to divest its sabcomeline programme, which it acquired through its February acquisition of Minster Pharmaceuticals, to BrainCells for an upfront fee and milestone payments together worth up to $51 million, as well as a royalty on sales.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Rii PLC
  • BioPartners Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Proximagen Ltd.
  • Senior Management
  • John Russell, Chmn. & Interim CEO
  • Contact Info
  • Minster Pharmaceuticals PLC
    Phone: (44) (0) 207 936 9921
    107-111 Fleet St.
    London, EC4A 2AB